Silicon Laboratories Inc. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) | ||||
| ||||
| Nine Months Ended | |||
| October 2,
|
| October 3,
|
|
Operating Activities |
|
|
|
|
Net income | $2,120,497 |
| $ 3,583 |
|
Adjustments to reconcile net income to cash provided by operating activities of continuing operations: |
|
|
|
|
Income from discontinued operations, net of income taxes | (2,183,884) |
| (97,721) |
|
Depreciation of property and equipment | 12,925 |
| 11,789 |
|
Amortization of intangible assets and other assets | 33,971 |
| 31,118 |
|
Amortization of debt discount and debt issuance costs | 17,278 |
| 14,946 |
|
Loss on extinguishment of convertible debt | 3,370 |
| 3,977 |
|
Stock-based compensation expense | 36,916 |
| 36,252 |
|
Deferred income taxes | (3,132) |
| (7,382) |
|
Changes in operating assets and liabilities: |
|
|
|
|
Accounts receivable | 22,573 |
| (2,902) |
|
Inventories | (11,320) |
| 12,499 |
|
Prepaid expenses and other assets | 27,598 |
| (5,602) |
|
Accounts payable | (4,522) |
| 6,103 |
|
Other current liabilities and income taxes | (10,981) |
| 3,608 |
|
Deferred revenue and returns liability | (1,657) |
| 2,643 |
|
Other non-current liabilities | (11,388) |
| 7,525 |
|
Net cash provided by operating activities of continuing operations | 48,244 |
| 20,436 |
|
|
|
|
|
|
Investing Activities |
|
|
|
|
Purchases of marketable securities | (1,212,572) |
| (418,227) |
|
Sales and maturities of marketable securities | 368,416 |
| 427,235 |
|
Purchases of property and equipment | (19,468) |
| (13,589) |
|
Purchases of other assets | (578) |
| (920) |
|
Acquisition of business, net of cash acquired | -- |
| (316,809) |
|
Net cash used in investing activities of continuing operations | (864,202) |
| (322,310) |
|
|
|
|
|
|
Financing Activities |
|
|
|
|
Proceeds from issuance of debt | -- |
| 845,000 |
|
Payments on debt | (140,572) |
| (618,729) |
|
Repurchases of common stock | (688,373) |
| (16,287) |
|
Payment of taxes withheld for vested stock awards | (21,393) |
| (17,562) |
|
Proceeds from the issuance of common stock | 8,619 |
| 8,155 |
|
Net cash provided by (used in) financing activities of continuing operations | (841,719) |
| 200,577 |
|
|
|
|
|
|
Discontinued Operations |
|
|
|
|
Operating activities | 69,685 |
| 106,527 |
|
Investing activities | 2,747,684 |
| (2,018) |
|
Net cash provided by discontinued operations | 2,817,369 |
| 104,509 |
|
|
|
|
|
|
Increase in cash and cash equivalents | 1,159,692 |
| 3,212 |
|
Cash and cash equivalents at beginning of period | 202,720 |
| 227,146 |
|
Cash and cash equivalents at end of period | $1,362,412 |
| $230,358 |
|